NLRP3 (D4D8T) Rabbit mAb
具體成交價以合同協議為準
- 公司名稱 上海優寧維生物科技股份有限公司
- 品牌 CST
- 型號
- 產地
- 廠商性質 代理商
- 更新時間 2024/7/5 16:20:14
- 訪問次數 911
聯系我們時請說明是化工儀器網上看到的信息,謝謝!
溫馨提示:優寧維所有產品和服務僅用于科學研究,不用于臨床等診斷及其他用途提供產品和服務(也不為任何個人提供產品和服務)!
反應性 | H M |
靈敏度 | 內源性 |
MW (kDa) | 110 |
來源/同種型 | 兔 IgG |
應用關鍵詞:
- WB- 蛋白質印跡法
- IP-免疫沉淀法
- IHC-免疫組織化學法
- ChIP-染色質免疫沉淀法
- IF-免疫熒光法
- F-流式細胞術
- E-P-ELISA 肽
物種交叉反應性關鍵詞:
- H-人
- M-小鼠
- R-大鼠
- Hm- 倉鼠
- Mk-猴
- Vir- 病毒
- Mi-水貂
- C-雞
- Dm-黑腹果蠅
- X-爪蟾
- Z-斑馬魚
- B-牛
- DG-犬
- PG-豬
- Sc-釀酒酵母
- Ce-秀麗隱桿線蟲
- Hr-馬
- All-預期所有物種
應用 | 稀釋度 |
---|---|
蛋白質印跡法 | 1:1000 |
免疫沉淀法 | 1:200 |
保存
保存在 10 mM sodium HEPES (pH 7.5)、150 mM NaCl、100 μg/ml BSA、50% 甘油和低于 0.02% 的中。-20℃ 保存。切勿分裝抗體。
background
The nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) protein family is a diverse family of cytoplasmic innate immune receptors. They are characterized by the presence of an amino-terminal effector domain, usually a caspase activation and recruitment domain (CARD) or a pyrin domain (PYD), followed by a NACHT domain and a carboxyl group involved in the recognition of pathogen-associated molecular patterns (PAMPs) Terminal leucine-rich repeats (LRRs) (1). NLR proteins play various roles in the innate immune response, including detection of pathogens, transcriptional activation of proinflammatory cytokines through NF-κB, transcriptional activation of type I interferons through IRF, and formation of inflammasomes that activate inflammatory caspases (1-7 ).NLRP3 is an inflammasome-forming NLR that activates caspase-1 to mature IL-1β and IL-18 (8). The NLRP3 inflammasome does not assemble until after a variety of microbial and endogenous stimuli, so it is unlikely that NLRP3 interacts directly with its activators (8). NLRP3 expression reaches highest levels in dendritic cells, monocytes and macrophages (9).
- Elinav, E. et al. (2011) Immunity 34, 665-79.
- Inohara, N. et al. (1999) J Biol Chem 274, 14560-7.
- Ogura, Y. et al. (2001) J Biol Chem 276, 4812-8.
- Sabbah, A. et al. (2009) Nat Immunol 10, 1073-80.
- Mariathasan, S. et al. (2004) Nature 430, 213-8.
- Agostini, L. et al. (2004) Immunity 20, 319-25.
- Martinon, F. et al. (2002) Mol Cell 10, 417-26.
- Franchi, L. et al. (2012) Nat Immunol 13, 325-32.
- Guarda, G. et al. (2011) J Immunol 186, 2529-34.